| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Merlin Thomas | Q56991969 |
| Derek P Chew | Q79135799 | ||
| Pupalan Iyngkaran | Q114409951 | ||
| P2093 | author name string | Christopher Reid | |
| Danny Liew | |||
| David L Hare | |||
| Peter McDonald | |||
| P2860 | cites work | Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension | Q24194304 |
| Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria | Q26797153 | ||
| Telmisartan and cardioprotection | Q26861422 | ||
| Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction | Q57243489 | ||
| Incidence of first heart failure hospitalisation and mortality in Aboriginal and non-Aboriginal patients in Western Australia, 2000–2009 | Q57387303 | ||
| Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids | Q57628874 | ||
| Improving the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting: The IMPROVE HF performance improvement registry | Q57630885 | ||
| Population-Based Analysis of Class Effect of β Blockers in Heart Failure | Q58665904 | ||
| Do patients with heart failure appropriately undergo invasive procedures post-myocardial infarction? Results from a prospective multicentre study | Q40105240 | ||
| Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. | Q43266275 | ||
| The epidemiology of heart failure in Australia | Q43541059 | ||
| Demystifying fixed and random effects meta-analysis. | Q43720868 | ||
| Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). | Q43865277 | ||
| Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: a meta-analysis of 72,128 patients | Q44074535 | ||
| ACP Journal Club. Interpreting meta-analyses in systematic reviews | Q44180526 | ||
| Surrogate end points in heart failure trials | Q44320864 | ||
| Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study. | Q45227937 | ||
| Late-onset heart failure after myocardial infarction: trends in incidence and survival | Q45781906 | ||
| Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction. | Q46026126 | ||
| High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database | Q46162624 | ||
| Trends in long-term cardiovascular mortality and morbidity in men and women with heart failure of ischemic versus non-ischemic aetiology in Western Australia between 1990 and 2005. | Q46205401 | ||
| Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice | Q46209368 | ||
| Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study | Q46731180 | ||
| A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure | Q46795772 | ||
| A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy | Q46965416 | ||
| Guidelines for translational research in heart failure | Q47573464 | ||
| Who is now responsible for discovering and warning about adverse effects of generic drugs? | Q50475380 | ||
| Complexity of management and health outcomes in a prospective cohort study of 573 heart failure patients in Australia: does more equal less? | Q51263489 | ||
| Telmisartan as a metabolic sartan: The first meta-analysis of randomized controlled trials in metabolic syndrome | Q51342885 | ||
| n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia | Q51355736 | ||
| The role of meta-analysis in the regulatory process for foods, drugs, and devices | Q52909484 | ||
| A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation | Q53141326 | ||
| Socioeconomic status and heart failure in Sydney. | Q54342149 | ||
| Phase 4 research: what happens when the rubber meets the road? | Q54471968 | ||
| Short‐term Effect of Verapamil on Coronary No‐Reflow Associated With Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐analysis of Randomized Controlled Trials | Q27013629 | ||
| Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients | Q27023161 | ||
| The meaning of translational research and why it matters | Q28264016 | ||
| In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events | Q28476590 | ||
| Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research | Q29547313 | ||
| Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials | Q29620299 | ||
| A five-phase model for clinical-outcome research | Q30433882 | ||
| A comparison of risk factors for mortality from heart failure in Asian and non-Asian populations: an overview of individual participant data from 32 prospective cohorts from the Asia-Pacific Region | Q30828094 | ||
| Survey of the quality of experimental design, statistical analysis and reporting of research using animals | Q30941851 | ||
| Is mortality from heart failure increasing in Australia? An analysis of official data on mortality for 1997-2003 | Q31080526 | ||
| Rural and urban differentials in primary care management of chronic heart failure: new data from the CASE study. | Q31111831 | ||
| Systematic review: antihypertensive drug therapy in black patients | Q31121688 | ||
| A validation study: how effective is the Hospital Morbidity Data as a surveillance tool for heart failure in Western Australia? | Q33380412 | ||
| Quality and availability of consumer information on heart failure in Australia | Q33392459 | ||
| Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data | Q33613135 | ||
| Ensuring medical device effectiveness and safety: a cross--national comparison of approaches to regulation | Q33880328 | ||
| Reproducibility in science: improving the standard for basic and preclinical research | Q34042907 | ||
| Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies | Q34051032 | ||
| A catalogue of reporting guidelines for health research | Q34091472 | ||
| Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information | Q34093100 | ||
| Effects of renin–angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: A systematic review and meta-analysis | Q34111724 | ||
| Deconstructing the drug development process: the new face of innovation | Q34190877 | ||
| The health services burden of heart failure: an analysis using linked population health data-sets | Q34245597 | ||
| Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials | Q34335356 | ||
| Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis | Q34380070 | ||
| Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis | Q34412986 | ||
| How to read a paper: Papers that summarise other papers (systematic reviews and meta-analyses) | Q34440404 | ||
| The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis | Q34532092 | ||
| EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population | Q34568746 | ||
| Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions | Q34614447 | ||
| Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. | Q34623044 | ||
| Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis | Q34644734 | ||
| Meta-analysis: impact of drug class on adherence to antihypertensives | Q34887070 | ||
| Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials | Q34997772 | ||
| The impact of renin–angiotensin–aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy | Q58977867 | ||
| Translational research: 4 ways to fix the clinical trial | Q59054253 | ||
| Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee | Q59637921 | ||
| Heterogeneity of Heart Failure Management Programs in Australia | Q60588328 | ||
| Uncovering a Hidden Epidemic: A Study of the Current Burden of Heart Failure in Australia | Q60588330 | ||
| Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials | Q61866091 | ||
| Adherence, adaptation and acceptance of elderly chronic heart failure patients to receiving healthcare via telephone-monitoring | Q63479479 | ||
| Economic end points in phase II trials | Q73599507 | ||
| Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure | Q73599538 | ||
| Design of phase II trials in congestive heart failure | Q73599542 | ||
| Surrogate end points in heart failure | Q78032634 | ||
| Recent changes in heart failure hospitalisations in Australia | Q79194063 | ||
| Impact of gender on outcomes in chronic systolic heart failure | Q79300426 | ||
| Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study | Q80146317 | ||
| Temporal trends in the frequency and longer-term outcome of heart failure complicating myocardial infarction | Q80534806 | ||
| [Clinical and Preclinical Heart Failure Research Network (REDINSCOR). Instituto de Salud Carlos III Cooperative Special Topic Research Networks] | Q80552596 | ||
| Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction--a meta-analysis | Q80960338 | ||
| Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis | Q81161791 | ||
| Key issues in end point selection for heart failure trials: composite end points | Q81362301 | ||
| Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials | Q81552190 | ||
| Impact of concomitant heart failure on outcomes in patients undergoing percutaneous coronary interventions: analysis of the Melbourne Interventional Group registry | Q83392273 | ||
| 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006 | Q83874799 | ||
| Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure | Q83970579 | ||
| Impact of Medication Nonadherence on Hospitalizations and Mortality in Heart Failure | Q84635111 | ||
| Postmarketing Surveillance | Q84866293 | ||
| Admission time, variability in clinical characteristics, and in-hospital outcomes in acute heart failure syndromes: findings from the ATTEND registry | Q85035255 | ||
| The cost of drug development: A systematic review | Q37831605 | ||
| Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review | Q37873923 | ||
| Novel therapeutic targets for the treatment of heart failure. | Q37893956 | ||
| Systematic reviews and meta-analysis: scientific rationale and interpretation | Q37896314 | ||
| Telmisartan for the reduction of cardiovascular morbidity and mortality | Q37960631 | ||
| Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis | Q37970579 | ||
| Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis | Q38010258 | ||
| Angiotensin Receptor Blockers Reduce Left Ventricular Hypertrophy in Dialysis Patients: A Meta-Analysis | Q38047213 | ||
| Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. | Q38074639 | ||
| The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes | Q38122865 | ||
| Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination | Q38168671 | ||
| Implementing guideline based heart failure care in the Northern Territory: challenges and solutions. | Q38189181 | ||
| Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis | Q38197227 | ||
| A systematic approach to chronic heart failure care: a consensus statement. | Q38240394 | ||
| A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients | Q38242658 | ||
| Technology-assisted congestive heart failure care | Q38317252 | ||
| Northern Territory perspectives on heart failure with comorbidities – understanding trial validity and exploring collaborative opportunities to broaden the evidence base | Q38338678 | ||
| Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). | Q38396011 | ||
| Medical product safety surveillance: how many databases to use? | Q38425381 | ||
| Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines. | Q38855941 | ||
| Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. | Q39343371 | ||
| Post-marketing surveillance of prescription drug safety: past, present, and future | Q39360686 | ||
| Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study. | Q39569317 | ||
| Chronic heart failure beyond city limits | Q39739642 | ||
| Inequitable provision of optimal services for patients with chronic heart failure: a national geo-mapping study. | Q39787264 | ||
| Why do phase III trials of promising heart failure drugs often fail? the contribution of “regression to the truth” | Q35570387 | ||
| Recommendations for the management of special populations: racial and ethnic populations | Q35587697 | ||
| Pharmacological therapy for myocardial reperfusion injury | Q35737715 | ||
| Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study | Q35798096 | ||
| Plasma and dietary omega-3 fatty acids, fish intake, and heart failure risk in the Physicians’ Health Study | Q36231651 | ||
| Fast parameters estimation in medication efficacy assessment model for heart failure treatment | Q36318002 | ||
| Toward phase 4 trials in heart failure: A social and corporate responsibility of the medical profession | Q36391299 | ||
| Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials | Q36456291 | ||
| Interpreting and understanding meta-analysis graphs--a practical guide. | Q36559341 | ||
| Drug discovery for heart failure: a new era or the end of the pipeline? | Q36724656 | ||
| Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta‐analysis | Q36792952 | ||
| Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial | Q36796494 | ||
| Phase II trials in heart failure: the role of cardiovascular imaging | Q36906123 | ||
| Plasma Phospholipid Long-Chain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults | Q36974431 | ||
| Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension | Q36993966 | ||
| Perindopril: do randomised, controlled trials support an ACE inhibitor class effect? A meta-analysis of clinical trials. | Q37041380 | ||
| Epidemiology and risk stratification in acute heart failure | Q37063731 | ||
| Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers | Q37105275 | ||
| Interpreting meta-analysis in systematic reviews | Q37178726 | ||
| Meta-analysis: Its strengths and limitations. | Q37205285 | ||
| The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. | Q37269661 | ||
| The preclinical basis of the therapeutic evaluation of losartan. | Q37272659 | ||
| Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics | Q37276490 | ||
| Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia | Q37328685 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| Systematic reviews as a tool for planning and interpreting trials | Q37399439 | ||
| Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure | Q37404258 | ||
| Access and quality of heart failure management programs in Australia | Q37545012 | ||
| Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review | Q37554671 | ||
| The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study | Q37609698 | ||
| Meta-analysis of small randomized controlled trials in surgery may be unreliable | Q37692370 | ||
| The effect of evidence-based medication use on long-term survival in patients hospitalised for heart failure in Western Australia | Q37709444 | ||
| Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis | Q37791983 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| biomedical investigative technique | Q66648976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 216-230 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Current cardiology reviews | Q26842280 |
| P1476 | title | Phase 4 Studies in Heart Failure - What is Done and What is Needed? | |
| P478 | volume | 12 |
| Q38855941 | Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines. |
| Q60918375 | Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age |
| Q61446690 | Risk stratification for coronary artery disease in multi-ethnic populations: Are there broader considerations for cost efficiency? |
| Q89949914 | The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground? |
Search more.